Come hear about our projects at the Contact meeting
Head of the Genomics Core Facility Leonardo Meza-Zepeda will at the NBS Contact meeting present two large projects on Personalized Cancer Medicine that the Core Facility is part of.
The projects Personalized Cancer Medicine and Lung cancer Pilot Project will be presented by Leonardo Meza-Zepeda in two minisymposia at the 2013 NBS Contact meeting at Lillehammer. The first presentation will be in Minisymposia 3 at 5 pm, the second in Minisymposia 1 at 6 pm, both on Thursday January 31.
Personalized Cancer medicine is a prioritized area for the National Health Service in Norway, and the Personalized Cancer Medicine consortium have recieved two major grants to among other objectives provide a national network for implementation of personalised cancer medicine in Norway.
News
Due to a resent hacker attack to the OUS IT system, we currently are unable to receive or send emails to the rr-research domain. Until further notice please use this email to contact us “genomics.cf.oslo@gmail.com”
The HiSeq 4000 build upon the existing HiSeq 2500 platform using the new HiSeq X patterned flow cell technology, providing unparalleled speed and performance. The dual-flow cell HiSeq 4000 System delivers the highest throughput and lowest price per sample across multiple applications. The new sequencer will provide users will faster turnaround time (run time is 3 days compared to 6-11 days in HiSeq 2500) and higher quality, more data per run and longer reads (150 bp paired-end).
Contact Information:
genomics.cf.oslo@gmail.com
Visiting address:
Genomics Core Facility (Room 3-F8-04)
Department of Core facilities
Institute for Cancer Research
New OCCI-building
Norwegian Radium Hospital
Ullernchaussen 66, Lamell 3, 2B
NO-0379 Oslo, NORWAY
+47 - 9183 2772 Laboratory
+47 - 9183 3425 Office
Daily Leader Core Facility
Susanne Lorenz, PhD
Head of Core Facility
Leonardo A. Meza-Zepeda, Dr. philos.
................................................................
................................................................
